NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”) today announced the completion of the sale of its assets related to HOOKIPA’s HB-400 program and certain of its assets related to HOOKIPA’s HB-500 program to Gilead Sciences, Inc. (“Gilead”). In connection with the consideration and evaluation of HOOKIPA’s long-term prospects and strategies by HOOKIPA’s board of directors, on May 21, 2025 HOOKIPA entered into an asset purchase agreement (“Asset Purchase Agree ...

Core Insights - Clearmind Medicine Inc. has announced a U.S. patent application for its non-hallucinogenic compound MEAI, aimed at treating cocaine addiction, enhancing its intellectual property portfolio [1][2][4] - Cocaine use disorder is a significant global health issue with no FDA-approved treatments, presenting a market opportunity projected to grow from $1.36 billion in 2025 to $2.03 billion by 2032 [2] - MEAI is designed to modulate serotonin and dopamine pathways, potentially offering a safer alternative to existing behavioral interventions for addiction [3][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics for under-treated health problems, including addiction [1][4] - The company currently holds nineteen patent families with 31 granted patents and plans to pursue additional patents to strengthen its intellectual property [5] Market Context - The global market for cocaine addiction treatment is experiencing urgent demand for new solutions, highlighting the potential impact of Clearmind's developments in this area [2][3]

Core Insights - Zai Lab Limited will participate in two investor conferences in November and December 2025, including the Jefferies Global Healthcare Conference and Citi's 2025 Global Healthcare Conference [1] Company Overview - Zai Lab Limited is a research-based, commercial-stage biopharmaceutical company operating in China and the United States, focusing on innovative products in oncology, immunology, neuroscience, and infectious diseases [2] Upcoming Events - The Jefferies Global Healthcare Conference will take place on November 19, 2025, at 8:30 AM GMT in London, and the Citi's 2025 Global Healthcare Conference will occur on December 2, 2025, at 1:00 PM ET in Miami, Florida [1] - Live webcasts of these events will be available on Zai Lab's Investor Relations page, with archived replays accessible for up to 90 days [1] Financial Reporting - Zai Lab is set to announce its third quarter 2025 financial results and recent corporate updates on November 6, 2025, before the U.S. equity markets open [6]

Core Insights - Adagene Inc. has initiated a Phase 2 clinical trial for muzastotug in combination with KEYTRUDA for patients with microsatellite stable colorectal cancer, with the first patient dosed in October 2025 [1][2] - The trial aims to confirm the optimal dosing for a subsequent Phase 3 trial, with completion anticipated in early 2027 and potential updates expected in 2026 [1][2] Phase 2 Clinical Trial Details - The trial will randomize patients to receive either 10 mg/kg or 20 mg/kg of muzastotug, with up to 30 patients per arm [1][4] - The primary endpoint is overall response rate (ORR), while secondary endpoints include duration of response (DOR), progression-free survival (PFS), and overall survival (OS) [4] Phase 1b/2 Trial Findings - In the Phase 1b/2 trial, 67 patients were treated with muzastotug, showing an ORR of 17% for the 10 mg/kg cohort and 29% for the 20 mg/kg cohort [3][4] - The median duration of response for the 10 mg/kg cohort was 6.2 months, while the median overall survival for the 10 mg/kg cohort was 19.4 months [5] Safety Profile - Muzastotug has been safely dosed at 20 mg/kg with less than 20% Grade 3 adverse events and no discontinuations, indicating a favorable safety profile compared to first-generation anti-CTLA-4 therapies [2][5] Company Overview - Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies, utilizing computational biology and artificial intelligence [7][8] - The company's lead program, ADG126 (muzastotug), targets regulatory T cells in the tumor microenvironment and is part of a broader pipeline leveraging its SAFEbody technology [9]

WALTHAM, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be participating in the following upcoming investor conferences in November: 2025 Truist Securities BioPharma Symposium, New York, NYThursday, November 6, 2025, Panel - 8:10 a.m. ETStifel 2025 Healthcare Confere ...

Core Insights - Dupixent (dupilumab) has been awarded the "Best Biotechnology Product" of 2025 by the Galien Foundation, recognizing its significant scientific innovation and impact on various allergic and atopic conditions [1][2] - It is the first and only therapy specifically targeting the IL-4 and IL-13 signaling pathways, which are key drivers of type 2 inflammation [1][2] Company Overview - Regeneron Pharmaceuticals, Inc. is a leading biotechnology company focused on developing life-transforming medicines for serious diseases [23] - The company utilizes proprietary technologies, such as VelocImmune, to create optimized fully human antibodies [22][24] Product Details - Dupixent is approved for eight indications globally, including atopic dermatitis, asthma, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, bullous pemphigoid, prurigo nodularis, and chronic obstructive pulmonary disease (COPD) [3][6] - More than 1 million patients are currently being treated with Dupixent worldwide [2][6] Scientific Significance - Dupixent was developed based on a hypothesis that many allergic and atopic diseases are driven by excess IL-4 and IL-13, with Phase 3 trials demonstrating significant clinical benefits [2][5] - It is the first dual blocker of IL-4 and IL-13 approved by the U.S. FDA, highlighting its unique position in the market [2][5] Clinical Development - Dupixent has been studied in over 60 clinical trials involving more than 10,000 patients, focusing on chronic diseases associated with type 2 inflammation [8][9] - The product is jointly developed by Regeneron and Sanofi under a global collaboration agreement [7] Future Prospects - Regeneron and Sanofi are exploring additional indications for Dupixent in Phase 3 trials, including chronic pruritus of unknown origin and lichen simplex chronicus [9]

SHANGHAI, Oct. 31, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the execution of an Amendment to its strategic collaboration agreement with Regeneron Pharmaceuticals, Inc. ("Regeneron"), a leading global biotechnology company. This amendment not only signifies a major upgrade in long-term partnership between the two companies, but also marks the beginning ...

This story was originally published on CFO.com. To receive daily news and insights, subscribe to our free daily CFO.com newsletter. Adam Elinoff | Agilent Technologies Adam Elinoff was appointed chief financial officer of scientific instruments maker Agilent Technologies, effective Nov. 17. Elinoff joins Agilent from biotechnology company Amgen, where he has held leadership roles for a total of 19 years, most recently as vice president of finance and treasurer. Elinoff was previously the regional CFO for E ...

Key Points The cancer-focused biotech surprised on the upside for both revenue and profitability in its latest reported quarter. Revenue rose by almost 40% year over year in that period. 10 stocks we like better than Guardant Health › Guardant Health (NASDAQ: GH) unveiled its latest set of quarterly results on Thursday, and the biotech's encouraging performance gave the stock significant upward momentum. The company's shares were up by 28% week to date as of early Friday morning, according to data c ...

Core Insights - Alector Inc. is highlighted as a promising investment opportunity under $3, particularly following the announcement of topline results from the Phase 3 INFRONT-3 clinical trial for its drug latozinemab (AL001) targeting frontotemporal dementia due to a progranulin gene mutation [1][4] Clinical Trial Results - The INFRONT-3 trial, a 96-week double-blind study conducted in collaboration with GSK, did not achieve its primary endpoint of slowing the progression of frontotemporal dementia as measured by the Clinical Dementia Rating plus National Alzheimer's Coordinating Center Frontotemporal Lobar Degeneration Sum of Boxes [2][3] Future Developments - Alector is also involved in the PROGRESS-AD trial, a global 76-week Phase 2 study evaluating nivisnebart (AL101/GSK4527226) for early Alzheimer's disease, with enrollment completed in April 2025 and trial completion expected in 2026, including an independent interim analysis planned for H1 2026 [3]